Skip to main content

Table 3 Background of patient who are taking warfarin

From: Safety of heparin bridging therapy for transrectal ultrasound-guided prostate biopsy in patients requiring temporary discontinuation of antithrombotic agents

 

Discontinuation of warfarin

P value

Without bridging

With bridging

Biopsy, n

49

19

 

Patients, n

46

18

 

Age (years)

72 (68, 76)

73 (71, 76)

0.406

PSA (ng/mL)

8.8 (5.4, 13.6)

10.5 (7.0, 14.9)

0.333

Diabetes, n

5 (10%)

5 (26%)

0.128

Hypertension, n

23 (47%)

7 (37%)

0.588

Concurrent antithrombotic agents

  

1.000

 Warfarin alone, n

34 (69%)

13 (68%)

 

 Warfarin + others, n

15 (31%)

6 (32%)

 

PT-INR (at a target level)

1.55 (1.19, 1.92)

1.89 (1.67, 2.32)

0.026

CHAD2 score

1 (1, 3)

1 (0, 3)

0.701

  1. Median and interquartile range (Q1, Q3) was used for consecutive variables. PT-INR: prothrombin time-international normalized ratio